Pasithea Therapeutics Corp. (KTTA)
0.5801
0.00 (0.00%)
USD |
NASDAQ |
Sep 04, 16:00
0.5801
0.00 (0.00%)
After-Hours: 20:00
Pasithea Therapeutics Enterprise Value : -26.37M for Sept. 3, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| September 03, 2026 | -26.37M |
| September 02, 2026 | -26.37M |
| September 01, 2026 | -26.95M |
| August 31, 2026 | -26.59M |
| August 28, 2026 | -27.05M |
| August 27, 2026 | -27.24M |
| August 26, 2026 | -26.72M |
| August 25, 2026 | -27.05M |
| August 24, 2026 | -28.89M |
| August 21, 2026 | -27.74M |
| August 20, 2026 | -30.06M |
| August 19, 2026 | -29.39M |
| August 18, 2026 | -29.14M |
| August 17, 2026 | -29.79M |
| August 14, 2026 | -29.71M |
| August 13, 2026 | -29.79M |
| August 12, 2026 | -29.39M |
| August 11, 2026 | -29.82M |
| August 10, 2026 | -29.93M |
| August 07, 2026 | -28.83M |
| August 06, 2026 | -30.94M |
| August 05, 2026 | -30.73M |
| August 04, 2026 | -30.39M |
| August 03, 2026 | -30.84M |
| July 31, 2026 | -30.40M |
| Date | Value |
|---|---|
| July 30, 2026 | -30.93M |
| July 29, 2026 | -30.73M |
| July 28, 2026 | -30.73M |
| July 27, 2026 | -30.73M |
| July 24, 2026 | -30.56M |
| July 23, 2026 | -29.72M |
| July 22, 2026 | -30.39M |
| July 21, 2026 | -30.57M |
| July 20, 2026 | -29.95M |
| July 17, 2026 | -30.73M |
| July 16, 2026 | -30.49M |
| July 15, 2026 | -29.79M |
| July 14, 2026 | -29.66M |
| July 13, 2026 | -29.39M |
| July 10, 2026 | -29.31M |
| July 09, 2026 | -29.06M |
| July 08, 2026 | -28.67M |
| July 07, 2026 | -28.40M |
| July 06, 2026 | -28.39M |
| July 02, 2026 | -27.39M |
| July 01, 2026 | -26.82M |
| June 30, 2026 | -28.54M |
| June 29, 2026 | -37.38M |
| June 26, 2026 | -36.95M |
| June 25, 2026 | -36.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 3.913B |
| Alnylam Pharmaceuticals, Inc. | 35.05B |
| Anika Therapeutics, Inc. | 267.88M |
| Savara, Inc. | 960.37M |
| Vericel Corp. | 2.003B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -5.274M |
| Total Expenses (Quarterly) | 5.274M |
| EPS Diluted (Quarterly) | -0.1643 |
| Earnings Yield | -272.3% |
| Normalized Earnings Yield | -276.38 |